Research ExplorerPublicationsEsomeprazole

Esomeprazole

Standard

Esomeprazole : prevention and treatment of NSAID-induced symptoms and ulcers. / Morgner, Andrea; Miehlke, Stephan; Labenz, Joachim.

In: EXPERT OPIN PHARMACO, Vol. 8, No. 7, 05.2007, p. 975-88.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Morgner, A, Miehlke, S & Labenz, J 2007, 'Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers', EXPERT OPIN PHARMACO, vol. 8, no. 7, pp. 975-88. https://doi.org/10.1517/14656566.8.7.975

APA

Morgner, A., Miehlke, S., & Labenz, J. (2007). Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers. EXPERT OPIN PHARMACO, 8(7), 975-88. https://doi.org/10.1517/14656566.8.7.975

Vancouver

Morgner A, Miehlke S, Labenz J. Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers. EXPERT OPIN PHARMACO. 2007 May;8(7):975-88. https://doi.org/10.1517/14656566.8.7.975

Bibtex

@article{23e7cb52836a4b00a31902927443997b,
title = "Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers",
abstract = "Non-steroidal anti-inflammatory drugs (NSAIDs) represent one of the most widely used drug classes. However, many patients complain of dyspeptic symptoms impairing their quality of life: ~ 20% of patients taking NSAIDs show endoscopic ulcers with or without symptoms, and up to 2% of chronic NSAID users will develop serious complications each year, such as bleeding or perforation, which are the cause of death in many patients. Coprescription of a proton pump inhibitor is one established option for the healing and prevention of NSAID-associated lesions of the upper gastrointestinal tract in patients at risk. Recent studies evaluated the clinical efficacy of esomeprazole in the management of gastrointestinal problems associated with the intake of selective and non-selective NSAIDs and aspirin.",
keywords = "Animals, Anti-Inflammatory Agents, Non-Steroidal, Anti-Ulcer Agents, Dyspepsia, Esomeprazole, Humans, Proton Pump Inhibitors, Stomach Ulcer, Journal Article, Review",
author = "Andrea Morgner and Stephan Miehlke and Joachim Labenz",
year = "2007",
month = may,
doi = "10.1517/14656566.8.7.975",
language = "English",
volume = "8",
pages = "975--88",
journal = "EXPERT OPIN PHARMACO",
issn = "1465-6566",
publisher = "informa healthcare",
number = "7",

}

RIS

TY - JOUR

T1 - Esomeprazole

T2 - prevention and treatment of NSAID-induced symptoms and ulcers

AU - Morgner, Andrea

AU - Miehlke, Stephan

AU - Labenz, Joachim

PY - 2007/5

Y1 - 2007/5

N2 - Non-steroidal anti-inflammatory drugs (NSAIDs) represent one of the most widely used drug classes. However, many patients complain of dyspeptic symptoms impairing their quality of life: ~ 20% of patients taking NSAIDs show endoscopic ulcers with or without symptoms, and up to 2% of chronic NSAID users will develop serious complications each year, such as bleeding or perforation, which are the cause of death in many patients. Coprescription of a proton pump inhibitor is one established option for the healing and prevention of NSAID-associated lesions of the upper gastrointestinal tract in patients at risk. Recent studies evaluated the clinical efficacy of esomeprazole in the management of gastrointestinal problems associated with the intake of selective and non-selective NSAIDs and aspirin.

AB - Non-steroidal anti-inflammatory drugs (NSAIDs) represent one of the most widely used drug classes. However, many patients complain of dyspeptic symptoms impairing their quality of life: ~ 20% of patients taking NSAIDs show endoscopic ulcers with or without symptoms, and up to 2% of chronic NSAID users will develop serious complications each year, such as bleeding or perforation, which are the cause of death in many patients. Coprescription of a proton pump inhibitor is one established option for the healing and prevention of NSAID-associated lesions of the upper gastrointestinal tract in patients at risk. Recent studies evaluated the clinical efficacy of esomeprazole in the management of gastrointestinal problems associated with the intake of selective and non-selective NSAIDs and aspirin.

KW - Animals

KW - Anti-Inflammatory Agents, Non-Steroidal

KW - Anti-Ulcer Agents

KW - Dyspepsia

KW - Esomeprazole

KW - Humans

KW - Proton Pump Inhibitors

KW - Stomach Ulcer

KW - Journal Article

KW - Review

U2 - 10.1517/14656566.8.7.975

DO - 10.1517/14656566.8.7.975

M3 - SCORING: Journal article

C2 - 17472543

VL - 8

SP - 975

EP - 988

JO - EXPERT OPIN PHARMACO

JF - EXPERT OPIN PHARMACO

SN - 1465-6566

IS - 7

ER -